Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA.
-
Authors
-
-
He, Kewen1
-
Zhang, Shaotong2
-
Shao, Liang L3
-
Yin, Jiani C4
-
Wu, Xue3
-
Shao, Yang W5
-
Yuan, Shuanghu6
-
Yu, Jinming7
-
1
Department of Radiology, Shandong Cancer Hospital affiliated to Shandong University, Jinan, Shandong, 250117, People's Republic of China; Department of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, People's Republic of China.
,
(China)
-
2
Department of Cardiology, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong, 250013, People's Republic of China.
,
(China)
-
3
Geneseeq Technology Inc., Toronto, Ontario, M5G 1L7, Canada.
,
(Canada)
-
4
Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, 210032, People's Republic of China.
,
(China)
-
5
Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, 210032, People's Republic of China; School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, 210029, People's Republic of China.
,
(China)
-
6
Department of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, People's Republic of China. Electronic address: [email protected]
,
(China)
-
7
Department of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, People's Republic of China. Electronic address: [email protected]
,
(China)
- Type
- Published Article
- Journal
-
Cancer letters
- Publication Date
-
Mar 01, 2020
- Volume
-
472
- Pages
-
108–118
- Identifiers
-
DOI: 10.1016/j.canlet.2019.12.004
-
PMID: 31837443
- Source
-
Medline
- Keywords
-
- Language
-
English
- License
-
Unknown
Abstract
Despite the common application and considerable efforts to achieve precision radiotherapy (RT) in several types of cancer, RT has not yet entered the era of precision medicine; the ability to predict radiosensitivity and treatment responses in tumors and normal tissues is lacking. Therefore, development of genome-based methods for individual prognosis in radiation oncology is urgently required. Traditional DNA sequencing requires tissue samples collected during invasive operations; therefore, repeated tests are nearly impossible. Intra- and inter-tumoral heterogeneity may undermine the predictive power of a single assay from tumor samples. In contrast, analysis of circulating tumor DNA (ctDNA) allows for non-invasive and near real-time sampling of tumors. By investigating the genetic composition of tumors and monitoring dynamic changes during treatment, ctDNA analysis may potentially be clinically valuable in prediction of treatment responses prior to RT, surveillance of responses during RT, and evaluation of residual disease following RT. As a biomarker for RT response, ctDNA profiling may guide personalized treatments. In this review, we will discuss approaches of tissue DNA sequencing and ctDNA detection and summarize their clinical applications in both traditional RT and in combination with immunotherapy. Copyright © 2019 Elsevier B.V. All rights reserved.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 08/13/2020 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at
https://www.ncbi.nlm.nih.gov/pubmed/31837443
